IL126267A0 - A novel composition for controlled and sustained transdermal administration - Google Patents

A novel composition for controlled and sustained transdermal administration

Info

Publication number
IL126267A0
IL126267A0 IL12626798A IL12626798A IL126267A0 IL 126267 A0 IL126267 A0 IL 126267A0 IL 12626798 A IL12626798 A IL 12626798A IL 12626798 A IL12626798 A IL 12626798A IL 126267 A0 IL126267 A0 IL 126267A0
Authority
IL
Israel
Prior art keywords
controlled
transdermal administration
novel composition
sustained transdermal
sustained
Prior art date
Application number
IL12626798A
Other languages
English (en)
Original Assignee
Permatec Tech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Permatec Tech Ag filed Critical Permatec Tech Ag
Publication of IL126267A0 publication Critical patent/IL126267A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/58—Adhesives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12626798A 1997-09-17 1998-09-17 A novel composition for controlled and sustained transdermal administration IL126267A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97MI002106A IT1294748B1 (it) 1997-09-17 1997-09-17 Formulazione per un dispositivo transdermico

Publications (1)

Publication Number Publication Date
IL126267A0 true IL126267A0 (en) 1999-05-09

Family

ID=11377881

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12626798A IL126267A0 (en) 1997-09-17 1998-09-17 A novel composition for controlled and sustained transdermal administration

Country Status (14)

Country Link
US (1) US6231885B1 (xx)
EP (1) EP0913158B1 (xx)
JP (1) JPH11152224A (xx)
KR (1) KR19990029891A (xx)
AR (1) AR019001A1 (xx)
AT (1) ATE238777T1 (xx)
AU (1) AU742399B2 (xx)
CA (1) CA2247767A1 (xx)
DE (1) DE69813988D1 (xx)
IL (1) IL126267A0 (xx)
IT (1) IT1294748B1 (xx)
NZ (1) NZ331904A (xx)
TW (1) TW493994B (xx)
ZA (1) ZA988421B (xx)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19828274C2 (de) * 1998-06-25 2002-11-28 Rottapharm Bv Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
US20020160995A1 (en) * 1998-08-03 2002-10-31 Easterling W. Jerry Medication and method for remediating existing scars through transdermal, topical delivery of calcium channel blockers
AU5325000A (en) * 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
DE19950066A1 (de) * 1999-10-16 2001-04-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einem Gehalt an Tulobuterol-hydrochlorid zur Verabreichung des Bronchodilatators Tulobuterol über die Haut
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
DE10015783C2 (de) * 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
KR20020037616A (ko) * 2000-11-15 2002-05-22 서경배 케토롤락의 경피흡수제제
TWI287455B (en) * 2000-12-05 2007-10-01 Noven Pharma Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US20040170672A1 (en) * 2001-03-07 2004-09-02 Thorsten Selzer Transdermal therapeutic system for administration of partial dopamine-d2 agonists
KR100846642B1 (ko) * 2001-03-07 2008-07-16 히사미쓰 세이야꾸 가부시키가이샤 첩부제
MXPA03008349A (es) * 2001-03-16 2004-10-15 Johnson & Johnson Parche transdermico para administrar fentanilo.
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE10114382A1 (de) * 2001-03-23 2002-09-26 Beiersdorf Ag Feuchtigkeitsaufnehmende Matrix auf Silikonbasis insbesondere zur Wundversorgung und/oder pharmazeutisch/kosmetischen Hautbehandlung
AU2002316053A1 (en) * 2001-05-01 2002-11-11 A.V. Topchiev Institute Of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
CA2445086C (en) * 2001-05-01 2008-04-08 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US20050215727A1 (en) * 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8541021B2 (en) * 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8840918B2 (en) * 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US20030018074A1 (en) * 2001-07-06 2003-01-23 Robert Kleiman Antiviral composition and treatment method
WO2003013611A1 (fr) * 2001-08-10 2003-02-20 Hisamitsu Pharmaceutical Co., Inc. Preparations a absorption par voie cutanee
CA2460352C (en) * 2001-08-17 2013-05-14 Lavipharm Laboratories Inc. Composition and transdermal drug delivery device
DE10159120B4 (de) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
US7921999B1 (en) * 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
US20060088579A1 (en) * 2002-02-07 2006-04-27 Shastri Venkatram P Transdermal drug delivery systems
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DK1480625T3 (da) * 2002-03-06 2008-10-27 Hexal Ag Transdermalt system med fentanyl
WO2003090729A1 (en) 2002-04-23 2003-11-06 Alza Corporation Transdermal analgesic systems with reduced abuse potential
WO2004000263A1 (en) 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
JP4354678B2 (ja) * 2002-08-28 2009-10-28 久光製薬株式会社 貼付剤
US20040086551A1 (en) 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
CA2729967C (en) * 2002-12-13 2018-01-16 Schering-Plough Healthcare Products, Inc. Use of a transdermal or transmucosal ingredient delivery device
DE10304988A1 (de) * 2003-02-07 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit verbessertem Hautklebeverhalten
AU2004220357B2 (en) 2003-03-10 2010-09-30 Astrazeneca Ab Novel process for the preparation of roflumilast
EP2319505A1 (en) * 2003-04-30 2011-05-11 Purdue Pharma L.P. Transdermal dosage form comprising an active agent component and an adverse agent component in a ratio from 1:10 up to 10:1
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
WO2005007020A2 (en) * 2003-07-03 2005-01-27 Corium International, Inc. Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
JP4694967B2 (ja) * 2003-07-31 2011-06-08 久光製薬株式会社 貼付剤
US20070059351A1 (en) * 2003-10-17 2007-03-15 Murrell George A C Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods
US20060286159A1 (en) * 2003-10-17 2006-12-21 Calvert Murrell George A Treatment of persistent active tendinopathy using transdermal glyceryl trinitrate providing durability of effect
US20060286158A1 (en) * 2003-10-17 2006-12-21 Calvert Murrell George A Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents
US20070053966A1 (en) * 2003-10-17 2007-03-08 Robert Ang Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue
AU2005210637B2 (en) 2004-01-30 2010-09-16 A.V. Topchiev Institute Of Petrochemical Synthesis Rapidly dissolving film for delivery of an active agent
CA2557354C (en) * 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Alkaloid formulations
EP2269650A3 (en) * 2004-08-03 2012-05-16 Vital Health Sciences Pty Ltd. Carrier for enteral administration
CA2576158C (en) * 2004-08-05 2020-10-27 Corium International, Inc. Adhesive composition
ES2265239B1 (es) * 2004-09-23 2008-02-01 Laboratorio Reig Jofre, S.A. Composicion farmaceutica para administracion transdermica.
ES2346895T3 (es) 2004-10-21 2010-10-21 Durect Corporation Sistemas de administracion transdermica.
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US20060188558A1 (en) * 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
ITMI20050477A1 (it) * 2005-03-23 2006-09-24 Bouty S P A Cerotto transdermico
JP5221343B2 (ja) 2005-06-17 2013-06-26 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 担体
US20110086086A1 (en) * 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
US7884158B2 (en) * 2005-09-06 2011-02-08 L'Oré´al Cosmetic compositions containing block copolymers, tackifiers and phenylated silicones
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
US8383149B2 (en) * 2005-09-23 2013-02-26 Alza Corporation High enhancer-loading polyacrylate formulation for transdermal applications
WO2007035940A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal norelgestromin delivery system
DE102005056393A1 (de) * 2005-11-24 2007-05-31 Grünenthal GmbH Multicyclische Verbindungen in druckempfindlichen Klebstoffen
US20070122699A1 (en) * 2005-11-30 2007-05-31 Rovcal, Inc. Electrochemical cells having improved gelling agents
US20070202155A1 (en) * 2006-02-03 2007-08-30 Cure Therapeutics, Inc. Low dose no donor-containing transdermal patch
US20070259026A1 (en) * 2006-04-20 2007-11-08 Robert Ang Vasodialating dressing for use with intravenous catheters
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
WO2008115224A2 (en) * 2007-03-20 2008-09-25 Bayer Healthcare Llc Method of analyzing an analyte
DE102007041557B4 (de) * 2007-08-29 2011-03-31 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend längliche Hohlkörper
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
WO2009052204A1 (en) * 2007-10-15 2009-04-23 Alza Corporation Once-a-day replacement transdermal administration of fentanyl
DE102007060175A1 (de) * 2007-12-13 2009-06-18 Johannes Gutenberg-Universität Mainz Quartärnisierung des Zusatzstoffs Aminoalkyl Methacrylat Copolymer E zur Verbesserung der Permeabilität und Löslichkeit von Arzneistoffen
EP2259780A2 (en) 2008-02-28 2010-12-15 Syntropharma Limited Pharmaceutical composition comprising naltrexone
US20090263456A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
EP2387394B1 (en) 2009-01-14 2018-05-02 Corium International, Inc. Transdermal administration of tamsulosin
US9320742B2 (en) * 2009-12-01 2016-04-26 Noven Pharmaceuticals, Inc. Transdermal testosterone device and delivery
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
RU2553350C2 (ru) 2010-03-30 2015-06-10 Фосфейдженикс Лимитед Трансдермальные пластыри
WO2011139420A2 (en) 2010-04-30 2011-11-10 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd AMINO-QUINOLINES AS KINASE INHIBITORS
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
CN102895358A (zh) * 2011-07-29 2013-01-30 苏州知微堂生物科技有限公司 一种三黄汤整合型新剂型制备技术及其生产方法
US9364487B2 (en) * 2011-11-04 2016-06-14 Agile Therapeutics, Inc. Dermal delivery compositions and methods
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
BR112015007872A2 (pt) 2012-11-02 2017-07-04 Teikoku Pharma Usa Inc composições transdermais de propinilaminoindano
US10137098B2 (en) 2014-05-28 2018-11-27 Teikoku Seiyaku Co., Ltd. Transdermal preparation
EP3169318B1 (en) 2014-07-18 2020-04-01 Buzzz Pharmaceuticals Limited Abuse deterrent opiod/opiod-antagonist transdermal patch
US9789070B2 (en) 2015-07-28 2017-10-17 Elc Management Llc Sheet packs for treating facial or body surfaces
CN108601732A (zh) 2015-12-09 2018-09-28 磷肌酸有限公司 药物制剂
WO2017131034A1 (ja) * 2016-01-28 2017-08-03 久光製薬株式会社 経皮吸収製剤
WO2018006069A1 (en) * 2016-06-30 2018-01-04 Teva Pharmaceuticals International Gmbh Improved formulations for transdermal pharmaceutical systems
US20190330260A1 (en) 2016-12-21 2019-10-31 Avecho Biotechnology Limited Process
US10406114B2 (en) * 2017-06-11 2019-09-10 Masoumeh Nasrollahzadeh Abyazani Antibiotic-loaded transdermal patch

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4764381A (en) 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
EP0573133A1 (de) 1988-10-27 1993-12-08 Schering Aktiengesellschaft Mittel zur transdermalen Applikation das Gestoden enthält
IL92537A (en) * 1988-12-15 1994-04-12 Riker Laboratories Inc Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5091186A (en) 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
SE8904296D0 (sv) 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5225198A (en) 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
EP0644746B1 (en) 1992-06-11 1999-09-15 Theratech, Inc. The use of glycerin in moderating transdermal drug delivery
EP0707465A4 (en) 1993-07-08 1997-04-16 Cygnus Therapeutic Systems MONOLITHIC MATRIX TRANSDERMAL DELIVERY SYSTEM
US5466465A (en) 1993-12-30 1995-11-14 Harrogate Holdings, Limited Transdermal drug delivery system
WO1995029678A1 (en) * 1994-04-28 1995-11-09 F.Hoffmann-La Roche Ag Pharmaceutical composition for transdermal delivery

Also Published As

Publication number Publication date
ZA988421B (en) 1999-03-17
CA2247767A1 (en) 1999-03-17
EP0913158A1 (en) 1999-05-06
KR19990029891A (ko) 1999-04-26
DE69813988D1 (de) 2003-06-05
TW493994B (en) 2002-07-11
NZ331904A (en) 1999-03-29
AU8423098A (en) 1999-04-01
JPH11152224A (ja) 1999-06-08
AU742399B2 (en) 2002-01-03
ATE238777T1 (de) 2003-05-15
EP0913158B1 (en) 2003-05-02
US6231885B1 (en) 2001-05-15
AR019001A1 (es) 2001-12-26
ITMI972106A1 (it) 1999-03-17
IT1294748B1 (it) 1999-04-12

Similar Documents

Publication Publication Date Title
ZA988421B (en) A novel composition for controlled and sustained transdermal administration
AU1302499A (en) Buffered drug formulations for transdermal electrotransport delivery
HUP0002209A3 (en) 4-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives and pharmaceutical compositions containing them
HUP9802983A3 (en) Composition for transdermal delivery
PL337348A1 (en) Pharmaceutic composition comprising a combination of piperidinylalkanol and a decongestant
GB9706089D0 (en) Pharmaceutical composition
EP0941039A4 (en) TRANSDERMAL ADMINISTRATION OF 7alpha-METHYL-19-NORTESTOSTERONE ("MENT")
AU8695698A (en) Pharmacologic drug combination in vagal-induced asystole
IL125820A0 (en) Therapeutic agent for diabetes and a pharmaceutical composition containing the same
EP0978288A4 (en) DRUG COMPOSITION
ZA96530B (en) Transdermal formulation
HUP9802070A3 (en) Transdermal formulation
AU2345695A (en) Pharmaceutical composition for transdermal delivery
GB9717444D0 (en) Pharmaceutical composition
HUP0002455A3 (en) Gastric-retained pharmaceutical composition
IL116999A0 (en) Transdermal formulation
GB9717428D0 (en) Pharmaceutical composition
IL122920A (en) Castrointestinal drug composition
PL322596A1 (en) Antiglucocorticoid drug
AU732214C (en) Biphenyl derivatives and drug composition
GB9705989D0 (en) Therapeutic composition
AU1143899A (en) Transdermal delivery of 3,4-diarylchromans
HUP0004132A3 (en) Rapidly soluble drug composition
GB9717770D0 (en) Pharmaceutical composition
GB2321190B (en) Pharmaceutical composition